Volume 4, Number 50
Monday, December 13, 2004



In this issue: (click heading to view article)
Cluster Analysis of Patients with Ocular Surface Disease, Blepharitis and Dry Eye
Posterior Sub-Tenon Triamcinolone vs. Orbital Floor Methylprednisolone for Posterior Uveitis
Microemulsion-Based Dexamethasone Eye Drop
Identifying Gene Expression Profile in Corneal Neovascularization by Immunology Related Macro Array
Briefly











Cluster Analysis of Patients with Ocular Surface Disease, Blepharitis and Dry Eye

Researchers at the Casey Eye Institute in Portland, OR, developed a classification system for blepharitis and dry eye based on a classification-tree model of a large group of subjects who were given a variety of objective physiologic tests.

The study evaluated 513 subjects. Some were healthy and some had blepharitis and dry eye. All were tested for tear volume, tear flow and tear turnover and were given the Schirmer test for dry eye. Investigators evaluated meibomian gland function by meibomian gland lipid expression for lipid volume and used lipid viscosity, evaporation and eyelid transillumination for meibomian gland drop-out. They subjected their data to cluster analysis and formulated a classification tree.

Cluster analysis most successfully grouped subjects by initially dividing them into two groups based on the presence or absence of gland drop-out and then by lipid viscosity and volume, Schirmer test results and evaporation. The analysis created nine categories. This division created an objective classification system that has clinical relevance. Normal subjects were distributed across several groups.

Using the classification tree developed in this study, blepharitis and dry eye can be classified with objective physiologic tests into clinically relevant groups that have common characteristics. The authors of the study believe that analysis establishes the central role of meibomian gland dysfunction in blepharitis and demonstrates the diverse characteristics of the normal population.

SOURCE: Mathers WD, Choi D. Cluster analysis of patients with ocular surface disease, blepharitis, and dry eye. Arch Ophthalmol 2004;122(11):1700-4.
Table of Contents











Posterior Sub-Tenon Triamcinolone vs. Orbital Floor Methylprednisolone for Posterior Uveitis

London’s Moorfields Eye Hospital recently conducted a non-randomized comparative prospective clinical study comparing the efficacy and side-effects of posterior sub-Tenon injection of triamcinolone acetonide (Kenalog) with orbital floor injection of methylprednisolone acetate (Depomedrone) in the management of posterior uveitis.

Sixty-four eyes from 60 consecutive patients with non-infectious posterior uveitis requiring treatment were allocated on an alternate one-to-one basis to receive either orbital floor methylprednisolone or sub-Tenon triamcinolone using standard procedures and assessed at six and 12 weeks. After five eyes of five patients who had received the same treatment bilaterally were excluded from the statistical analysis, 14 out of 29 eyes treated with orbital floor methylprednisolone and 10 out of the 30 eyes given sub-Tenon triamcinolone improved at six weeks. Investigators observed no statistically significant difference in the improvement rate between the two groups. However, two patients given triamcinolone had prolonged upper lid ptosis, which required surgery, and another two developed markedly raised intraocular pressure, neither of which occurred in the methylprednisolone-treated group. Researchers stress that the outcome of this study should be considered when choosing the preferred route of delivery of periocular corticosteroid in the treatment of posterior uveitis.

SOURCE: Ferrante P, Ramsey A, Bunce C, Lightman S. Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin Experiment Ophthalmol 2004;32(6):563-8.
Table of Contents











Microemulsion-Based Dexamethasone Eye Drop

Eye drops are the most-used dosage form by the ocular route, in spite of their low bioavailability. Because of their properties and numerous advantages, microemulsions are promising systems for topical ocular drug delivery. They can increase water solubility of the drug and enhance drug absorption into the eye. A Brazilian study aimed to develop and characterize an oil-in-water microemulsion containing dexamethasone, and evaluated its pharmacokinetics in rabbits after topical ocular application.

Researchers prepared the microemulsion by the titration technique and determined its physicochemical characteristics and stability. They studied ocular irritation and the pharmacokinetics of the system in white rabbits. The developed system showed an acceptable physicochemical behavior and presented good stability for three months. The ocular irritation test used suggested that the microemulsion did not provide significant alteration to eyelids, conjunctiva, cornea or iris. This formulation showed greater penetration of dexamethasone in the anterior segment of the eye and also release of the drug for a longer time when compared with a conventional preparation. The area under the curve obtained for the microemulsion system was more than twofold higher than that of the conventional preparation. Because the new system shows greater penetration in the eye, the investigators believe that it could allow for the possibility of a decreased number of applications of eye drops per day.

SOURCE: Fialho SL, da Silva-Cunha A. New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin Exper Ophthalmol 2004;32(6):626.
Table of Contents










Identifying Gene Expression Profile in Corneal Neovascularization by Immunology Related Macro Array

Investigators at Japan’s University of Tokyo have discovered differentially expressed genes newly identified in the context of corneal neovascularization, which they believe represent novel candidate factors for further functional studies of the mechanisms of corneal neovascularization.

The researchers performed mechanical denudation of corneal and limbal epithelium to induce corneal vascularization in mice. They harvested the corneas four days after operation, and they isolated total RNA from both normal and vascularized corneas and used it for the synthesis of cDNA probes. They hybridized 32P labeled exponential cDNA probes to mouse cDNA immunology arrays. To validate the gene expression patterns revealed by the cDNA expression array analysis, semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) and statistical analysis were performed to compare the normal and vascularized corneal samples.

Of 545 immunology-related genes on the arrays, six were upregulated and one was downregulated in the vascularized corneas, compared with the normal corneas. Semi-quantitative RT-PCR was performed on the six genes selected in the arrays study; results showed that calreticulin (calregulin), apolipoprotein E, HSP84 (HSP90-beta) and pleiotrophin were upregulated while interferon regulatory factor-1 was downregulated in the vascularized corneas compared with the normal corneas. These genes possess a number of biological functions including molecular chaperon, growth factor and transcriptional factors. The authors believe that their study data may provide new insight into the biological process of inflammation-induced corneal neovascularization.

SOURCE: Usui T, Yamagami S, Yokoo S, et al. Gene expression profile in corneal neovascularization identified by immunology related macroarray. Mol Vision 2004; 10:832-6.
Table of Contents







BRIEFLY
  • STUDY LINKS LEAD LEVELS TO CATARACTS IN MEN. A newly released study published in the Journal of the American Medical Association suggests that accumulated lead exposure, such as that commonly experienced by adults in the United States, may be an important unrecognized risk factor for cataract in men. Scientists at Boston"s Brigham and Women"s Hospital measured tibial (cortical and patellar (trabecular) bone lead levels by K X-ray fluorescence between 1991 and 1999 in a subset of participants in the Normative Aging Study (NAS), a Boston-based longitudinal study of aging in men. Among the first 795 NAS participants to have bone lead levels measured, they studied 642 men aged 60 years and older who had sufficient eye examination information available. They also measured blood levels of lead. Cataract was identified in 122 of the 642 men. Those with the highest tibia lead level were 2.7 times more likely to develop cataract than those with the lowest levels; after additional adjustment for pack-years of cigarette smoking, diabetes, blood lead levels and intake of vitamin C, vitamin E and carotenoids, the risk was 3.2 times that of those exposed to the lowest lead levels. Patients with the highest patella lead levels also were at increased risk of cataract, but the trend was not significant; blood lead levels, which are more indicative of short-term exposure levels, were not significantly associated with cataract. The investigators believe that the study is the first evidence suggesting that accumulated lead exposure may be an important and unrecognized risk factor for cataract.
    SOURCE: Schaumberg DA, Mendes F, Balaram M, et al. Accumulated lead exposure and risk of age-related cataract in men. JAMA 2004;292:2750-4.

  • ISTA SPREADING AGENT EARNS FDA APPROVAL. Ista Pharmaceuticals has received FDA approval for its single-use version of Vitrase, a solution used to boost the dispersion and absorption of other injected drugs during eye surgery. In May 2004, the FDA approved a larger 6,200-USP-unit multipurpose vial of Vitrase, a hyaluronidase ovine injectable spreading agent. The smaller dose (150 USP units) will be more cost-effective and easier to use, according to Ista. The company plans to launch both vial sizes early in the first quarter of 2005. Vitrase is also undergoing studies as a treatment for vitreous hemorrhage.

Table of Contents



 Check Yearly. See Clearly. Open Your Eyes To the Opportunities.
It"s only been up and running a few short weeks. Yet, it"s already clear that the Check Yearly. See Clearly.(SM) marketing campaign is opening consumers" eyes to the benefits of regular eye exams. Call the Vision Council of America at 800-424-8422 today or visit checkyearly.com for your free promotional materials.